What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class I recall involving a specific batch of prescription medication distributed by Fresenius Kabi USA, LLC. This particular recall centers on Morphine Sulfate Injection, USP, which is marketed for use in clinical settings for pain management. The product in question is packaged as 2 mg/mL strength within 1 mL single-dose Simplist prefilled syringes. These syringes are designed for either intramuscular or intravenous administration and are strictly available by prescription (Rx only). While the primary intent of this recall is to address a critical labeling error, it is important to understand exactly which physical items are affected to ensure that medical professionals and patients can identify them accurately.
The specific units subject to this recall are identified by precise National Drug Code (NDC) numbers. The "Unit of Use" NDC Number is 76045-004-01, which typically refers to the individual package configuration found in a clinical supply chain. Additionally, the "Unit of Sale" NDC Number is 76045-004-11, which denotes how the product is sold or billed. The affected inventory is tied to Lot Number 6402820, with an expiration date listed as December 2028. This means that while the medication itself may still be chemically stable and within its shelf life, it cannot be legally or safely dispensed due to the labeling discrepancy.
Fresenius Kabi, headquartered in Lake Zurich, Illinois, is the manufacturer responsible for this recall. The distribution pattern for these affected syringes was nationwide across the United States, meaning hospitals, clinics, pharmacies, and other healthcare facilities in all 50 states may potentially hold this inventory. The recall was officially initiated on August 4, 2026. A Class I classification by the FDA indicates that this is the most serious type of recall, suggesting a reasonable probability that the use of this product will cause serious adverse health consequences or death. This high-level classification underscores the urgency for healthcare providers to immediately inspect their stock and isolate any units matching the specific lot and NDC details provided above.
It is crucial to note that while the packaging may appear consistent with standard Morphine Sulfate Injection products, the actual content does not match the label. This discrepancy creates a significant risk of medication error in fast-paced medical environments. Healthcare teams must verify their current supply against these specific identifiers—particularly Lot 6402820 and the associated NDC numbers—to prevent any further distribution or administration of this particular batch. If you are a healthcare provider, checking your immediate inventory against these details is the first step in mitigating risk.
The hazard, explained
This recall centers on a critical failure in labeling integrity that creates a dangerous potential for medication error. Specifically, the issue involves Fresenius Kabi USA, LLC’s Morphine Sulfate Injection, USP, 2 mg/mL, 1 mL single-dose Simplist prefilled syringes. The physical defect is a mix-up at the manufacturing or packaging stage: certain syringes that are packaged and labeled as containing Morphine actually contain Dilaudid (hydromorphone). According to FDA records, the MicroVault-labeled products identified in this recall contain Dilaudid 0.5 mg/0.5 mL instead of the intended Morphine 2 mg/1 mL.
To understand why this is a Class I hazard—the most serious classification used by regulatory agencies—we must look at the pharmacological differences between these two drugs. Both morphine and hydromorphone are potent opioid analgesics used to manage severe pain. However, they are not interchangeable on a one-to-one basis due to significant differences in potency and dosing protocols. Hydromorphone is substantially more potent than morphine. The specific error identified here involves a syringe that delivers 0.5 mg of hydromorphone in a volume of 0.5 mL, rather than the labeled 2 mg of morphine in 1 mL.
The danger arises from the clinical context in which these medications are typically administered. In settings such as hospitals, clinics, or home care, healthcare providers rely on visual confirmation of the label to ensure they are administering the correct drug and dose. If a provider assumes the syringe contains morphine based on the outer packaging or the printed label, they may administer it without verifying the actual contents. Because the volume and appearance of prefilled syringes for different opioids can be similar, a visual check alone is insufficient to catch this error if the label itself is incorrect.
The potential for harm is multifaceted. If a patient is prescribed a specific dose of morphine for pain management, receiving hydromorphone instead introduces an unpredictable variable into their treatment plan. Conversely, and perhaps more immediately dangerous, is the risk of respiratory depression. Opioids suppress the central nervous system's drive to breathe. While the doses involved here are relatively small (0.5 mg), administering a potent opioid like hydromorphone to a patient who is not tolerant to it, or to a patient whose pain regimen does not account for such potency, can lead to severe sedation, slowed breathing, or other life-threatening complications. This is particularly critical in emergency situations where seconds count and trust in packaging accuracy is paramount.
Furthermore, this mix-up disrupts the entire chain of safety checks. Pharmacy verification processes, electronic prescribing systems, and nursing administration records all likely reference "Morphine." When the physical product does not match the digital or paper record, a systemic failure occurs. The medication given is not just a slightly different dose; it is a completely different chemical entity with different onset times, durations of action, and side effect profiles. This disconnect between the documented treatment plan and the actual substance injected is what makes this labeling error so profoundly risky for patient safety.
Who is most at risk
The primary group affected by this specific recall consists of healthcare professionals and patients who rely on Fresenius Kabi’s Morphine Sulfate Injection for pain management. Because the product in question is a prescription-only medication intended for intramuscular or intravenous use, the immediate risk is not to the general public stumbling upon an item at home, but rather to individuals currently under active medical care where this specific prefilled syringe was administered. The confusion arises from a critical labeling error: what appears on the outer packaging and label as Morphine 2 mg/1 mL actually contains Dilaudid (hydromorphone) 0.5 mg/0.5 mL. While both drugs are potent opioids used for pain relief, they are distinct chemical entities with different potencies, metabolisms, and side effect profiles. Therefore, the people most at risk are those who received this specific lot (6402820) expecting morphine but were instead given a different opioid agent.
Vulnerable populations, particularly the elderly and patients with compromised kidney or liver function, face heightened dangers in this scenario. Morphine and hydromorphone are processed differently by the body. Hydromorphone is significantly more potent than morphine on a milligram-for-milligram basis. If a patient’s dosage was calculated specifically for morphine sulfate, receiving hydromorphone could lead to an unintended overdose effect, even if the volume injected appears correct. For elderly patients, whose bodies naturally metabolize drugs more slowly and who often take multiple other medications, this unexpected shift in opioid type can precipitate severe respiratory depression, extreme sedation, or hypotension (dangerously low blood pressure). Their physiological reserve is lower, making them less able to tolerate sudden changes in medication potency.
Additionally, patients with a history of substance use disorder or those who are opioid-tolerant may experience unexpected withdrawal symptoms or adverse reactions if their expected medication profile is altered. The "Class I" classification of this recall by the FDA indicates that there is a reasonable probability that the use of this product will cause serious adverse health consequences or death. This underscores that the risk is not merely theoretical; it is acute and immediate for anyone receiving this specific syringe. Healthcare providers must be vigilant in verifying lot numbers, as the visual similarity between the products can lead to human error in busy clinical settings. Patients and their caregivers should also be aware that if they were treated with this product on or after August 4, 2026, there is a potential for receiving the wrong medication, which could result in inadequate pain control or unexpected toxicity depending on individual sensitivity to hydromorphone.
Finally, individuals with allergies or sensitivities specific to one opioid but not the other are at risk of allergic reactions. While both are opioids, excipients and chemical structures differ. A patient who tolerates morphine well might react adversely to hydromorphone or its formulation components. This makes accurate identification crucial for anyone with a documented history of adverse drug reactions. The nationwide distribution means that no geographic location is immune to this risk, affecting patients across all states where Fresenius Kabi supplies healthcare facilities.
How to tell if you have the recalled item
If you are a healthcare professional or work in a pharmacy setting, verifying whether you possess the specific units of Morphine Sulfate Injection recalled by Fresenius Kabi USA, LLC requires precise attention to detail. Because this recall involves a critical labeling mix-up where a MicroVault device labeled as Morphine actually contains Dilaudid, relying on visual inspection alone is dangerous and insufficient. You must cross-reference three distinct identifiers: the National Drug Code (NDC), the Lot Number, and the Expiration Date. If even one of these elements does not match the recall data exactly, the product is likely safe from this specific issue. However, if all three match, you must assume the syringe contains the wrong medication and treat it as a high-priority safety concern.
First, locate the National Drug Code (NDC) on the packaging. This recall affects two specific NDC numbers. For the "Unit of Use" packaging, look for NDC 76045-004-01. For the "Unit of Sale" packaging, look for NDC 76045-004-11. These numbers are typically printed on the outer carton and the secondary packaging labels. Fresenius Kabi products are distributed nationwide within the USA, so possessing this NDC does not automatically mean you have a bad unit, but it is the primary filter for determining if your inventory falls under this specific recall action.
The most critical step is checking the Lot Number and Expiration Date. The recall is strictly limited to Lot number 6402820 with an expiration date of December 2028 (12/2028). This lot information is printed directly on the prefilled syringe label and the outer carton. Do not rely on the drug name printed on the label, as the hazard here is that the label incorrectly identifies the contents. The MicroVault device may be labeled "Morphine 2 mg/1 mL," but the actual content is Dilaudid 0.5 mg/0.5 mL. Therefore, you must ignore the drug name for identification purposes and focus exclusively on the alphanumeric Lot code and the date. If your stock shows any other lot number or a different expiration date, it is not part of this recall.
Additionally, confirm the product specifications to ensure you are looking at the correct form factor. The recalled items are 2 mg/mL Morphine Sulfate Injection, USP, in 1 mL single-dose Simplist prefilled syringes intended for Intramuscular or Intravenous use. These are Rx-only products manufactured by Fresenius Kabi in Lake Zurich, IL. If you have a different concentration, a different volume, or a different brand of prefilled syringe, this recall does not apply to you. Always double-check the Lot number against 6402820 before making any decisions about dispensing or discarding the medication.
What to do — step by step
If you are a healthcare provider, pharmacist, or facility administrator who currently possesses the affected Morphine Sulfate Injection, USP, 2 mg/mL, 1 mL single-dose Simplist prefilled syringes, your immediate priority must be patient safety. Because this is a Class I recall—the most serious category indicating a reasonable probability that the product will cause serious adverse health consequences or death—you cannot treat this as a routine inventory discrepancy. The core issue here is a critical labeling mix-up involving the MicroVault system. Specifically, syringes from Lot #6402820 (expiration date 12/2028) are labeled as Morphine but actually contain Dilaudid (hydromorphone) 0.5 mg/0.5 mL. This is not a minor dosage error; it is a complete substitution of one potent opioid for another with different potency profiles and clinical indications.
First, you must immediately stop using these syringes in any patient care setting. Do not administer them under any circumstances, even if the label appears correct at a quick glance. The visual similarity between the packaging for Morphine and Dilaudid can be deceptive, which is precisely why the MicroVault labeling error is so dangerous. If you have these items in stock, remove them from your dispensing areas, pharmacy shelves, or automated dispensing cabinets right now. Isolate them physically away from other medications to prevent accidental selection by staff who may be rushing during an emergency.
Next, conduct a thorough audit of your inventory. Check your records against the specific details provided in this recall notice. You are looking for Unit of Use NDC Number 76045-004-01 or Unit of Sale NDC Number 76045-004-11, manufactured by Fresenius Kabi USA, LLC in Lake Zurich, IL. Verify that the lot number is exactly 6402820 and that the expiration date is 12/2028. If you cannot confirm these details with absolute certainty, assume the product is part of the recall and treat it as unsafe. Document every unit found during this audit, noting quantities and locations.
Here is the most critical gap in the current information: The official recall facts provided do not state the specific remedy instructions from Fresenius Kabi or the FDA regarding return procedures, refunds, or replacements. In a real-world scenario, you would typically contact your distributor or Fresenius Kabi directly for a recall code and shipping label. However, based strictly on the available data, there are no explicit instructions given for how to return the product or what financial compensation is offered. You should treat this as a potential emergency communication gap. Contact your medical supplier immediately to inquire if they have received updated guidance from Fresenius Kabi regarding the disposition of these defective units.
Finally, if you have already administered any of these syringes to a patient, do not wait for symptoms to appear. Monitor the patient closely for signs of opioid overdose or unexpected pharmacological effects that differ from what Morphine would typically produce. Report any adverse events to the FDA’s MedWatch program and consult with your institution’s risk management team immediately. Because the remedy is not stated in the provided facts, you must assume the worst-case scenario: that these units are completely unsalvageable and must be destroyed according to your facility’s hazardous waste protocols until further official guidance is received.
Your refund, repair, or replacement options
If you are currently holding one of the recalled Morphine Sulfate Injection prefilled syringes from Fresenius Kabi USA, LLC, your immediate priority is to stop using the product and secure a safe way to dispose of it or return it. However, a critical detail in this specific recall notice requires careful attention: the official FDA report does not explicitly state the remedy for this incident. This means that standard procedures for refunds, replacements, or returns are not clearly defined in the public record provided. While this might feel unsettling, it is important to understand that in Class I drug recalls involving potential labeling mix-ups—such as the one where a Dilaudid syringe was incorrectly labeled as Morphine—the primary focus of regulatory agencies is on removing the dangerous product from the supply chain and preventing accidental administration, rather than processing financial transactions for end-users.
Because the remedy is not stated, you should not assume that there is an automatic reimbursement or a direct mail-in return process available. In many pharmaceutical recalls, especially those involving hazardous drug substitutions like swapping an opioid analgesic (Dilaudid) for another (Morphine), the "remedy" is effectively the cessation of use and proper disposal. For patients, this usually means contacting your prescribing physician or pharmacist immediately to obtain a replacement prescription with correctly labeled medication. They will guide you on how to safely discard the recalled syringe, often through designated drug take-back programs or specific hazardous waste protocols, rather than sending it back to the manufacturer.
If you are a healthcare provider or pharmacy inventory manager dealing with this recall, the lack of stated remedy in the initial notice suggests that Fresenius Kabi likely communicated specific return instructions directly to their distribution partners and medical facilities. You should check your internal communications from Fresenius Kabi or contact their customer service line for detailed logistics on how to return the affected lots (6402820) with expiration date 12/2028. Do not attempt to ship these items back without explicit authorization, as improper handling of controlled substances can lead to legal and safety complications.
In the absence of clear refund or replacement terms in the public recall data, your best course of action is proactive communication. If you purchased this item recently and are concerned about costs, keep your receipt and documentation of the recall notice. While the FDA does not oversee consumer refunds for drug recalls, manufacturers sometimes offer goodwill gestures. However, do not wait for an unsolicited offer. Instead, rely on your healthcare provider to ensure you have the correct medication (Morphine or an alternative) without delay. The priority is ensuring that no one receives Dilaudid by mistake when Morphine was prescribed, a mix-up that can lead to serious adverse health events due to differences in potency and patient tolerance.
Ultimately, do not attempt to repair the labeling or use the syringe for any purpose. The integrity of the medication inside is compromised by the potential for confusion with another potent drug. Treat this as a total loss of the product's utility for your intended medical need. Focus on obtaining a new, correctly labeled prescription through your healthcare provider and disposing of the recalled unit safely according to local hazardous waste guidelines.
What can happen if you ignore it
When a medication is mislabeled in this manner, the risks extend far beyond a simple administrative error. The core danger here lies in the fundamental difference between two powerful opioids: morphine and hydromorphone (the active ingredient in Dilaudid). While both are used to manage pain, they are not interchangeable without precise medical calculation. Hydromorphone is significantly more potent than morphine by weight. If a patient or healthcare provider believes they are administering a standard dose of morphine sulfate 2 mg/1 mL, but the syringe actually contains Dilaudid 0.5 mg/0.5 mL, the concentration and potency per milliliter are drastically different. This discrepancy creates a high potential for accidental overdose.
The immediate consequence of ignoring this recall is the administration of the wrong drug at the wrong intensity. For patients who are opioid-naive or have lower tolerance levels, receiving hydromorphone when morphine was prescribed can lead to severe respiratory depression. The lungs may slow down too much or stop breathing entirely, a condition that can be fatal without immediate medical intervention. Even for patients with established tolerance, the unpredictability of the mix-up disrupts their carefully managed pain regimen, potentially leading to either dangerous sedation or unexpected withdrawal symptoms if the pain is not adequately controlled by the substituted agent.
Beyond the acute physical dangers, there are significant secondary risks related to treatment continuity. If a patient experiences an adverse reaction due to the wrong medication, they may require emergency care, hospitalization, or a change in their overall treatment plan. This disrupts their recovery process and places additional strain on healthcare systems. Furthermore, because this is a Class I recall—the most serious category used by the FDA—it indicates that there is a reasonable probability that the use of this product will cause serious adverse health consequences or death. Ignoring the warning does not make the defect disappear; it simply leaves you exposed to the unmitigated risk.
- Respiratory Failure: The most critical risk is slowed or stopped breathing, which can lead to brain damage or death.
- Hemodynamic Instability: Incorrect opioid dosing can cause dangerous drops in blood pressure and heart rate irregularities.
- Loss of Trust in Care: Receiving the wrong medication undermines confidence in the supply chain and may delay future necessary treatments due to fear or confusion.
It is important to note that while specific injury reports for this exact lot are not detailed in the initial recall notice, the nature of the hazard—labeling a potent opioid under the name of another—creates a universal risk profile. The danger is not theoretical; it is rooted in pharmacology. By ignoring the recall, you are essentially gambling with your physiological response to a high-risk drug. The safest path is always immediate discontinuation and consultation with your healthcare provider to ensure any doses already taken are monitored appropriately and that your future prescriptions are verified against the correct NDC numbers.
Staying safe: broader tips
When dealing with high-alert medications like injectable opioids, the margin for error is incredibly thin. A single misread label or confused vial can lead to serious harm, which is why building robust personal and household safeguards is just as important as responding to a specific recall. The most effective way to protect yourself and your loved ones starts with understanding that visual similarity between different medications is a well-known hazard in healthcare. Dilaudid and Morphine, for example, may share similar packaging aesthetics or be stored near each other, making "look-alike" errors a real risk. To counter this, always rely on the printed name and concentration rather than just the color of the liquid or the shape of the syringe. If you are managing medications at home, consider using distinct storage containers for different drug classes or asking your pharmacist to use tall-man lettering (like MO-rphine and DIL-audid) to create visual breaks that help your brain distinguish between them.
Another critical layer of safety is proactive communication with your healthcare providers. Never assume you know the name or dosage of a medication just because you have taken it before; always verify the label every single time, even if the prescription looks familiar. If you are administering injections at home, take a moment to pause and read the label aloud before breaking the seal. This simple act engages a different part of your brain, reducing the chance of automatic pilot errors. Additionally, keep a written log of all medications, including lot numbers and expiration dates, in a dedicated health binder or a secure digital app. This not only helps you track what is in your cabinet but also makes it significantly easier to identify affected products if a new recall is announced.
Stay informed by regularly checking official sources for safety alerts. The FDA website and the Drug Recall database are reliable, free resources that provide timely updates on product recalls. Subscribing to email alerts from these agencies can ensure you receive information directly, rather than relying on social media rumors or outdated news cycles. Furthermore, educate your entire household about the dangers of medication mix-ups. If multiple caregivers are involved in your care, establish a clear protocol for verifying medications before administration. By combining vigilance, clear communication, and reliable information sources, you create a safety net that protects you far beyond any single recall event.
- Always read the full label, including concentration and lot number, not just the drug name.
- Use tall-man lettering or distinct storage methods to separate look-alike drugs.
- Verify medications with your pharmacist if anything looks unusual or unfamiliar.
- Sign up for FDA recall alerts to stay current on safety issues.